FOS and osteoporosis: Liu44 further demonstrated in a mouse orthopedic study that a singleton therapeutic agent for osteoporosis can gain a coupled effect on the stimulation of bone formation by the Wnt/GSK3β/β-catenin pathway and on the suppression of bone resorption by the NF-κB/c-fos/NFATc1 pathway.